240 related articles for article (PubMed ID: 27472670)
1. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
3. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
[TBL] [Abstract][Full Text] [Related]
4. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
Tsai PC; Liu TW; Tsai YS; Ko YM; Chen KY; Lin CC; Huang CI; Liang PC; Lin YH; Hsieh MY; Hou NJ; Huang CF; Yeh ML; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
Medicine (Baltimore); 2017 Jun; 96(22):e6984. PubMed ID: 28562549
[TBL] [Abstract][Full Text] [Related]
5. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Lee SH; Jin YJ; Shin JY; Lee JW
Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
Ok KS; Jeong SH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Bae SH; Lee HC
Medicine (Baltimore); 2016 Aug; 95(35):e4594. PubMed ID: 27583874
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
8. Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.
Akpo EI; Sbarigia U; Wan G; Kleintjens J
Drugs R D; 2015 Dec; 15(4):335-49. PubMed ID: 26416653
[TBL] [Abstract][Full Text] [Related]
9. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
12. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
14. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
Wright M; Grieve R; Roberts J; Main J; Thomas HC;
Health Technol Assess; 2006 Jul; 10(21):1-113, iii. PubMed ID: 16750059
[TBL] [Abstract][Full Text] [Related]
15. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
Harris RJ; Thomas B; Griffiths J; Costella A; Chapman R; Ramsay M; De Angelis D; Harris HE
J Hepatol; 2014 Sep; 61(3):530-7. PubMed ID: 24824282
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
18. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
20. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
